1140P Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA
E. Gérard(Université de Bordeaux), Caroline Robert(Institut Gustave Roussy), Philippe Bernard(Hôpital Dupuytren), Célèste Lebbé(Inserm), Stéphanie Perrier(Université de Strasbourg), Émilie Lanoy(Université Paris-Sud), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), E. Maubec(Inserm), Délphine Legoupil(Centre Hospitalier Régional Universitaire de Brest), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Laurent Mortier, M-A. Viguier(Hôpital Robert-Debré), G. Quéreux(Nantes Université), S. Trabelsi-Messai(Centre Hospitalier Universitaire de Grenoble), Eve‐Marie Neidhardt(Centre Léon Bérard), E. Wierzbicka(Centre Jean Bernard), S. Garnier(Sanofi (France)), P. Celérier(Centre Hospitalier de La Rochelle), M. Dinulescu(Centre Eugène Marquis), Charlée Nardin(CHU Dijon Bourgogne)
Cited by 5
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k